Newsletter November 2008

EHA Newsletter May 2007 > 2

newsletterthe official newsletter for members of the EHA

November 2008

New Jersey, United States by Marc Rudoltz

> We also look forward. The prepara-tions for the 14th Congress in Berlin are in full swing. To enlighten you on how the educational and scientific program of the annual congress is put together, Radek Skoda has written a very informative ar-ticle about the SPC and the SPC AB.

The annual congress of EHA is one, al-beit important, instrument to promote education and lifelong learning in hema-tology. For instance, EHA would like to reach out to those who are unable to come to the annual congress. Also, de-spite our efforts to arrive at a compre-hensive and well balanced educational program at the annual congress, not all topics in the field of hematology can be covered. Here, I would like to focus on those instruments that may be a little less known to you.

To achieve greater outreach and to cover niche topics EHA organizes two-day tu-torials and workshops, it webcasts its annual congress’ educational sessions,

and has developed training online (EHA-Tol). What EHATol exactly is, is explained in this issue by Gina Zini, who, together with the EHA executive office, shows great dedication in making available five self-evaluation tests every three months. I kindly invite you to take these tests yourself. Furthermore, plans are under way to have the webcasts themselves CME accredited and to extend the web-casts to the workshops. In the end, the goal is to combine these learning tools into a blended learning experience.

Another aspect of education concerns not so much how we learn, but what we learn. Recently, the European Commis-sion has awarded a network of European national societies of hematology, the Eu-ropean School of Haematology (ESH), the Universities of Uppsala and Liverpool, and EHA a grant of up to € 600,000. The network’s name is H-Net and it aims to further develop the European Hematolo-gy Curriculum by identifying and mea-suring gaps in hematological knowledge

President’s Message:

Education in hematology:

the annual congress and more

Willem Fibbe

In this issue we look back at the 13th Congress in Copenhagen. We are happy

to announce that the congress yielded a record number of participants, over

6,600, and its program was of highest scientific and educational quality. This

success is largely due to the efforts of the Scientific Program Committee

(SPC) and its Advisory Board (SPC AB), which I would like to thank for

fulfilling their tasks so proficiently. Also, I would like to thank the sponsors

for their contribution to make the congress possible. I believe that a creative

collaboration with pharmaceutical partners is essential for positive

developments in any field of medicine.

and skills across Europe. The results will serve to target the gaps with existing and novel educational tools. In addition, H-Net will develop an online portfolio sys-tem which identifies educational needs of individual hematologists and offers suggestions to meet them. In coordinat-ing H-Net, EHA reinforces its dedication to arrive at a truly harmonized curricu-lum for European hematologists, raising competence levels and, ultimately, im-proving patient care and public health. I encourage you to read Eva Hellström-Lindberg’s contribution to this issue which describes the grant application process and the details of the H-Net’s ambitions.

Willem FibbeEHA President

2 > EHA Newsletter November 2008

ContentsPresident’s Message 2

H-Net 3

Translational research 4

EHATol 5

Editorial: Collaboration with pharma 6

Scientific Working Groups 7

Young investigator award 9

Wine and health 12

SPC and SPC AB 11

13th Congress 12

Collaboration ESH-EHA 15

Letter to the Editor 16

Overview EHA Committees an Units 17

Current members of the EHA Board of Directors 18

Upcoming congresses 18

EHA Executive Office 19

> In 2005 the national societies of he-matology in Europe, the European School of Haematology (ESH) and EHA jointly developed the European Hematology Curriculum. The Passport is a booklet designed for hematologists in training to check off subjects within the specialty, and the level mastered (ranging from awareness to competence). The trainee’s mentor confirms completion of each subject with a signature.

The Curriculum Passport aims to pro-mote the harmonization of qualifications and the mobility of hematologists throughout Europe. Harmonization was achieved after the national societies of hematology, ESH, and EHA, agreed on what constitutes a hematologist. The Curriculum Passport also promotes mo-bility, since different mentors can take

The makings of the European hematologist: H-Net“Yes, we can!” Echoing Barack Obama’s primary campaign slogan, Nancy Hamilton

and Thom Duyvené de Wit of the EHA Executive Office responded to my question.

It was over lunch at the January 23, 2008 board meeting in Amsterdam that I asked

if the EHA Executive Office has the capacity to make a European Commission

application for a grant to promote the implementation of the Curriculum Passport.

The deadline for submission was, however, February 29, 2008.

responsibility for different sections, allowing trainees to receive part of their education in one country, and part some-where else.

To cut a long story short, the strenuous efforts (and nocturnal working practices) of D Jasmin of ESH, of C Hok-Toh, P Re-bulla, A Urbano, and L Degos of the EHA curriculum committee, and of C Smand and the others of the EHA Executive Of-fice made the impossible possible. Final-ly, a night taxi ride to the headquarters of DHL near Amsterdam airport secured the all important date-stamp - February 29, 2008.

The application we sent that night was named ‘European Network for Harmoni-sation of Training in Haematology’; H-Net. It was sent in response to a call for

proposals issued by the directorate gen-eral Training and Education of the Euro-pean Commission. We applied for a Leonardo da Vinci network grant in the Lifelong Learning Program. The aim of H-Net is to further implement a harmo-nized curriculum for Hematology in Eu-rope. The core of the project consists of two phases. First, a survey will be under-taken of recently graduated hematolo-gists to assess their qualifications, then the results will be compared to the rec-ommendations expressed in the Curricu-lum Passport. The survey should allow H-Net to identify gaps in hematology training throughout Europe. For instance, we may observe that in country A, re-spondents score below the recommen-dations with respect to their knowledge and competence in the area of bone mar-row failure while in country B respon-dents consistently achieve low scores in the diagnosis of immunophenotyping by flow cytometry. Such information, sum-marized in a “European expression map for competence in hematology”, would enable informed decision making. Na-tional societies, national authorities, and individuals themselves, can decide on targeted additional education. Converse-ly taking into account their national con-text, countries may decide against ad-dressing situations they feel are not

EHA Newsletter November 2008 > 3

relevant to their population. In Nordic countries, for example, awareness rath-er than competence may be considered adequate for thalassemia major. In es-sence, H-Net survey results would en-able decision making to be based on fact rather than assumption, and allow com-parisons to be made against European benchmarks. In the second phase H-Net will use the information to tailor existing educational tools, such as workshops, tutorials, and webcasts. The results will also be used to develop a new education-al instrument called the Hematology Master-Class, to fit the educational needs of hematologists and organize them in the countries where they are most needed.

Furthermore, as part of H-Net individual hematologists will be able to create on-line personal profiles, known as the He-matology Portfolio, not unlike those of network websites, such as LinkedIn, MySpace, or FaceBook.

In the portfolio applications, which are being developed by the University of Upp-sala Learning Lab, one of the partners of H-Net, hematologists can enter their

own qualifications which will be com-pared to the recommendations of the Curriculum Passport allowing personal gaps to be identified. The Hematology Portfolio will then automatically make training suggestions specific to the indi-vidual educational needs of the hematol-ogist, which may be workshops, tutori-als, training opportunities organized by third parties, or recommendations from other portfolio holders. Ultimately, the portfolio system should become a widely used professional network of hematolo-gists throughout Europe.

With the European Commission aiming to promote mobilization of health profes-sionals and improve competence across the board, the H-Net project undoubtedly has implications that go beyond hema-tology. Currently health education orga-nization and content remain a national prerogative, with the European Commis-sion having no jurisdiction. The Commis-sion realizes that harmonization of quali-fications will only take place if European professionals themselves convince their national authorities of the need for edu-cational reform. H-Net plans to meet this challenge by organizing two policy

conferences to bring together the na-tional authorities and the European Commission to discuss the road map towards a harmonized curriculum for hematology and, possibly, other medi-cal specialties.

Friday June 13 - the second day of the 13th EHA Congress in Copenhagen - turned out to be our lucky day. The Euro-pean Commission couldn’t have chosen a better moment to inform us that our application had passed the evaluation: most of the people who worked on the project were there, so we managed a cel-ebration drink, or two.

Now, the hard work starts in earnest, and all involved are very excited be-cause H-Net provides us with the op-portunity to work together again on an interesting and important project. I hope, having read this article that you will agree.

Eva Hellström-Lindberg, EHA Past President and Chair of the EHA Curriculum CommitteeKarolinska University Hospital, Stockholm, Sweden

> The TRTH program, first proposed at the 2006 ASH-EHA leadership meet-ing, in Orlando, Florida, is currently be-ing planned along similar lines to the ASH Clinical Research Training Institute, a program that focuses on Phase I and II clinical trials.

The proposed format of the TRTH pro-gram, which is being targeted at clini-cians, translational scientists and bio-

Translational research boost for Europe A scheme to create a new training program in translational research,

encompassing both malignant and non-malignant hematology is currently

being planned in a joint initiative between the EHA and American Society of

Hematology (ASH). The Translational Research Training in Hematology (TRTH)

program is intended to boost standards of translational research in Europe,

an area that has been identified as under resourced.

medical students, is for participants to attend a six day residential course. Subjects likely to be covered in the ‘bench to bedside’ course include, di-agnostics, bio banking, bio statistics, bio informatics, candidate gene testing and stem cell research. In addition, EU legislation, rules, directives and guide-lines related to good clinical practice will be discussed, and sessions cover-ing issues relevant to grant applica-

tions and scientific paper writing will be planned. Participants will bring their own translational research pro-posals as part of the application pro-cess for the TRTH program. These pro-posals will be discussed in interactive sessions, with the goal of improving the quality of grant submissions. Op-portunities for “sustained mentoring” will be offered at follow up sessions scheduled to coincide with the EHA and ASH annual meetings.

Issues that still remain to be resolved in-clude eligibility for participation and re-view of the applications. Another impor-tant open item is funding of the scheme. We will keep you posted as this exciting initiative unfolds.

Ivo Touw, Co-Chair TRTH Subcommittee Erasmus Medical Center, Rotterdam, The Netherlands


> In 2006 EHA launched an innovative new project, EHA Training Online (EHA-Tol) for scientists and clinicians involved in the field of hematology. EHATol is an online distance learning tool, providing a readily accessible and constantly updat-ed content for training, education, and CME, with clinical cases presented and the opportunity for on-line self assess-ment.

What is a Clinical Case?Each clinical case, consisting of 14-19 chapters begins with the disease history, followed by descriptions of clinical ex-aminations, blood tests, cytogenetics and other diagnostic studies. The diagnosis and treatment recommendations are then described. According to the latest statistics, each clinical case was visited by an average of 143 users.

What is a CME Test Case?There are three parts to a CME Test Case -the introduction- (history of the disease), questions and results. Each self-evaluation test comprises six multiple choice ques-tions, with users allowed three attempts to respond correctly to all six questions in or-der to earn one CME credit point.

In August 2008 we extended the number of self assessment tests available, with each set now including five cases. The result is that users of the EHATol plat-form may now earn up to 20 CME credit

EHATol distance learning tool gains popularity

points per year by correctly completing the self-evaluation tests.

EHATol is becoming increasingly popu-lar, with more than 4000 users from 60 different countries having already updat-ed their knowledge using the EHATol platform.

The number of visitors in the first three quarters of 2008 increased by more then 30 per cent compared to the same period in 2007 (see figure 2).

In addition, the average length of ses-sions and the number of connections made each day, increased significantly.

Join now!Every three month a new set of the self assessment cases will become available online. EHATol is free of charge and available on the EHA website. If you would like to get access to clinical and CME Test cases please register via www.ehatol.org.

Prof. Gina Zini, MDChair of the EHATol UnitCatholic University of Sacred Heart, Rome, Italy

Figure 2: number of visitors of EHATolFigure 1

The EHATol unit met in Copenhagen


Collaborations with the pharmaceutical industry‘The proper basis for a marriage is mutual misunderstanding!’ Oscar Wilde.

> There has always been a symbiosis between the pharma-ceutical industry and the medical profession. Although certain-ly not a marriage, the relationship possesses similar qualities, despite the fact that neither party can ever truly divorce! The protagonists come from different backgrounds but share simi-lar desires. The loyalty of the pharmaceutical companies is to satisfy their shareholders, while the primary role of physicians is to provide the best medical care for their patients. Pharma-ceutical companies are, of course, in the business of manufac-turing drugs which benefit patients, and physicians depend on the industry to develop new and effective compounds.Dr M Greaves, from the University of Aberdeen, addressed both the possible tensions and opportunities for collaboration at the EHA annual meeting in June 2008. He began by quoting David Blumenthal’s statement from the New England Journal of Medicine: ‘when a great profession and the forces of capitalism interact, drama is the likely result’. He pointed out that re-search and development is declining in the industry due to a combination of patent expiration and generic competition, to-gether with the huge costs involved in bringing new drugs to the market. It is predicted that between 2007 and 2012, $ 67 billion will be lost from the top pharmaceutical companies in the USA.

Greaves pointed out that 'conflicts of interest' occur when indi-viduals have material gains, irrespective of financial value, that could influence or be perceived as influencing their opinions, decisions or actions in relation to patient care or the conduct of research. Potential conflicts have happened to all of us in the form of hospitality, attendance at conferences, and gifts, al-though we always claim that our judgement is not affected. A more difficult situation arises with clinical trials, especially in Europe. Because of difficulties with cost and indemnity, the number of ‘investigator-led trials’ has decreased and the num-ber of industry sponsored trials increased. Coupled with this is the payment for enrolling patients in industry-led tri-als. It must be remembered, however, that Health Services do NOT provide much support for conferenc-es and even light lunches at clinical meetings are provided by industry in many hospitals. The industry invests large amounts of money supporting educa-tion, bringing new treatments to the attention of doc-tors and supporting biomedical research. Educational support is commonly in the form of an unrestricted grant but industry sponsored clinical trials are more likely to be associated with positive outcomes than in-vestigator–led trials. Hopefully, a change in legisla-tion in Europe will make investigator–led trials easier to conduct without endangering the public.Although we must work together, it behoves the med-ical profession to be advocates for their patients. The regulatory bodies are constantly criticised, not always justifiably. If they are too cautious the public becomes upset by delays in introducing new agents, which may

be beneficial, and if the regulator releases new drugs without adequate testing they are admonished for not protecting pa-tients! Drug costs are now a huge issue for society, especially when linked to efficacy. It is quite amazing when a number of drugs with similar modes of action, but different development histo-ries, are similarly priced without any regard to their research and development costs!Tyrosine Kinase inhibitors (TKI’s) are examples of drugs which have totally changed the outlook for patients with Chronic My-eloid Leukemia (CML). However this disease has been trans-formed into a chronic illness and thus patient numbers are ac-cumulating. It is estimated that in the USA there soon will be 250,000 patients alive with CML, representing an annual cost somewhere in the region of € 7,5 billion for TKI’s. While the FDA does not take cost into account, countries – for example the UK - restrict new agents on the basis of cost-effectiveness, often resulting in a public outcry! With other expensive drugs, efficacy is difficult to demonstrate. The FDA approved a cholesterol-lowering agent in 2002 after a small number of clinical trials, which included 3,900 patients! In the absence of proven efficacy against heart attacks the drug earned billions of dollars for the company, presumably due to the robust advertising campaign. We would all agree (as men-tioned in a previous newsletter) that all clinical trials should be registered and the results, whether favourable or not, be made available to the public.Finally I am always intrigued by serendipity, especially in medi-cine. Although we live in an age of ‘certainty’ and people speak about focused research, it remains that many great medical developments still happen by chance and hopefully will contin-ue to do so in the future.

Shaun Mc CannEditor in Chief


Spotlight on Scientific Working GroupsIn 2008, EuroFlow was launched as the latest addition to the EHA Scientific Working Groups (SWG’s), bringing the total

number of groups to eleven. The main objectives of the EHA Scientific Working Groups are to create scientific networks

that both promote high quality science during the annual congress and attract basic scientists to meetings. To complete

the picture of SWG’s - some of whom featured in earlier issues of the Newsletter - we high-light the recent activities of

five of the groups.

Scientific Working Group on Granu-locyte and Monocyte Disorders

> The EHA SWG on granulocyte and monocyte disorders was established in 2005 during the 10th EHA Congress in Stockholm, Sweden. The main goal is to promote co-operation between clinicians and scientists involved in basic, transla-tional and clinical research in the field of granulocyte and monocyte disorders. Un-der this remit, scientific sessions during the 13th EHA Congress, covered topics on clinical and molecular diagnosis of neu-tropenias and unknown aspects of the role of neutrophils in innate immunity, stimulating interesting discussions in the audience that included for the first time clinicians, basic scientists and trainees in hematology. In addition, a major high-light for the year was the 3rd Neutropenia Network Conference, that took place in Crete, Greece, September 26-27, 2008, under the auspices of EHA and covered acquired and congenital neutropenias in a clinical, laboratory, cellular, and mo-lecular biology settings.

Helen Papadaki, ChairUniversity Hospital of Heraklion, Heraklion Crete, Greece

Scientific Working Group on Mul-tiple Myeloma

> At the 13th Congress of the Europe-an Hematology Association, the SWG on Multiple Myeloma hosted a scientific meeting, “The Myeloma Stem Cell” chaired by Pieter Sonneveld (Rotterdam, the Netherlands) and Hans E Johnsen (Aalborg, Denmark). First, Hans E Johns-en introduced the concept and scientific background of the myeloma stem cell, while Martin Perez Andres (Salamanca, Spain) addressed the B- cell hierarchy in B-cell malignancies and myeloma, de-

fining various B-cell compartments that may carry early clonal characteristics. Surinder Sahota (Southampton, UK) de-scribed molecular approaches to track the myeloma compartment and identify distinct profiles for pre-plasma cells that may belong to the myeloma clone. Pieter Sonneveld presented gene expression data of myeloma patients, introducing the concept of undertaking molecular profiles of chemo resistance in myeloma stem cells. Finally, Karin Vanderkerken (Brussels, Belgium) presented data of the 5TMM myeloma mouse model, which serves as a pre-clinical model for my-eloma (stem-) cell analysis.

Pieter Sonneveld, ChairErasmus Medical Center, Rotterdam, The Netherlands

Scientific Working Group: The European Study Group on MRD-Detection in ALL (ESG MRD-ALL)

> Originating from a group of 15 MRD-laboratories from the I-BFM study

group and the BIOMED-2 Concerted Action group, the European Study Group on MRD-detection in ALL (ESG MRD-ALL) has provided a framework for stan-dardizing, improving and comparing molecular MRD-diagnostics using Ig/TCR-gene rearrangements as RQ-PCR targets. Through 13 quality control ‘rounds’ with subsequent problem reso-lution meetings, common guidelines have been developed regarding both technical aspects and issues regarding interpretation of data (see: Van der Velden et al., Leukemia 2007;21:604-611). At the same time, the group has grown, now representing nearly 40 lab-oratories from Europe, Asia and Austra-lia, with its remit extended to cover MRD-diagnostics in malignant lympho-ma. The ESG MRD-ALL SWG, provides a framework for clinical study groups who want to use MRD diagnostics within their treatment protocols.

Thorsten Raff, ChairUniversity Hospital Schleswig Holstein, Kiel, Germany

The current EHA Scientific Working Groups are:

Scientific Working Group 1: Chronic Myeloid LeukemiaScientific Working Group 2: Granulocyte and Monocyte disordersScientific Working Group 3: Multiple MyelomaScientific Working Group 4: Myelodysplastic SyndromesScientific Working Group 5: Myeproliferative DisordersScientific Working Group 6: Quality of Life and SymptomsScientific Working Group 7: ThrombocytopeniasScientific Working Group 8: ESG-MRD-ALLScientific Working Group 9: Pharmacokinetics, pharmacogenetics &

pharmacodynamicsScientific Working Group 10: Red Cell and IronScientific Working Group 11: EuroFlow

To find out more about the Scientific Working Groups, check our website at: www.ehaweb.org


Scientific Working Group on Phar-macokinetic, Pharmacodynamic and Pharmacogenetic

> Chemotherapy – despite intensive research to find more specific treatment to target tumour cells - remains the corner stone of the majority of hemato-logical protocols. Most treatment proto-cols today are empirical and based on clinical experience. Despite long clinical use, little information is available about the mechanisms of action, individual-ization of those factors affecting thera-peutic efficacy and last but not least, in-teractions with other drugs. The Pharmacokinetic, Pharmacody-namic and Pharmacogenetic SWG aims to improve understanding of the mech-anisms of action of cytostatic drugs, to establish data-bases for EHA mem-bers, to organize and design random-ized PK/PD multi-centre studies, to provide help in designing and coordi-nating studies and to introduce thera-peutic drug monitoring and dose ad-justment to optimize individual chemotherapy treatment. The hope is that implementation of PK/PD/PG knowledge of cytostatics will ultimately improve treatment strategies and pa-tient outcomes.

Moustapha Hassan, ChairKarolinska University Hospital, Stockholm, Sweden

Scientific Working Group Euro-Flow: Flow cytometry for fast and sensitive diagnosis and follow-up of haematological malignancies

> Laboratory diagnostics of hemato-logical malignancies has three major ap-plications: establishing diagnosis, prog-nostic classification, and evaluation of treatment effectiveness. While molecular techniques have brought new insights into classification and monitoring of treatment effectiveness, they are frequently time consuming (taking two to three days), not applicable for all patients, and unable to focus on cellular subpopulations without prior purification. Flow cytometric immu-nophenotyping is the sole technique ful-filling requirements of high speed, broad applicability at diagnosis and during fol-low-up, and accurate focusing on malig-nant cell populations using membrane-bound and intracellular proteins as targets. Innovations are needed in flow cytometry, such as development of novel antibodies, novel immunobead technolo-gy, eight-color immunostaining protocols, and novel flow cytometry software for fast and easy interpretation of complex data and for automated pattern recognition, all of which are key objectives for the Euro-Flow consortium (EU-FP6 project LSHB-CT-2006-018708). This needs a multidis-ciplinary translational research approach using cutting edge technologies and bio-logical data arising from genomic re-search, which can be addressed best via

close collaboration between industry and academia. The EuroFlow consortium con-sists of two SME’s and ten diagnostic re-search groups, composed of experts in the fields of flow cytometric and molecu-lar diagnostics.

The EuroFlow Consortium is developing new software for fast and easy handling of large data sets and for integration of eight -color stainings into a single multi-color data file; standardization of eight -color immunostaining protocols for fast and easy flow cytometric diagnosis and classification of hematological malig-nancies (as well as evaluation of treat-ment effectiveness); multiplex immuno-bead assays for detection of fusion proteins and oncoproteins per disease category (particularly ALL and AML); and software for automated pattern recogni-tion of normal, reactive, and aberrant (malignant) leukocyte populations in blood and bone marrow. In addition, we are looking to create large data bases with 100s of well-defined normal, reac-tive and malignant cell samples, which can be used as ‘templates’ for fully auto-mated comparisons with patient sam-ples. As soon as the projects have been completed and approved, the results will be shared at Scientific Working Group sessions of the annual EHA meetings.

J van Dongen, ChairUniversity Medical Center, Rotterdam, The Netherlands

SWG chairs meeting: T Raff, C Camaschella, M Hasan, U Jäger, H Pahl and J van Dongen


Young investigator award to study CDX2 in AMLStefan Fröhling: Winner of the EHA José Carreras

Foundation Young Investigator Fellowship 2008

> It is a great honor for me to be the recipient of this year’s EHA José Carre-ras Foundation Young Investigator Fel-lowship, particularly given the high stan-dard of previous beneficiaries as well as the high quality of the applications con-sidered this year.

I first learned about the EHA Fellowship Program in 2002 when I attended the 7th Congress of EHA in Florence. Since that time, I have been appreciative of the ef-forts made by the EHA in promoting the career development of young scientists involved in hematologic research.

My application for an EHA Fellowship was motivated by a com-bination of factors. First, based on the excellent track record of past recipients, I realized that an EHA Fellowship provides a superb platform for young investigators to pursue a career in academic hematology. Second, I was encouraged to apply for an EHA Fellowship by my academic mentors, Prof Hartmut Döhner from my home institution (University Hospital of Ulm, Germany) and Dr Gary Gilliland (Harvard Medical School, Bos-ton, USA), my current supervisor. Lastly, during my postdoc-toral fellowship, I had the privilege of working with Dr Brian Huntly (Cambridge Institute for Medical Research, UK), who had received the EHA José Carreras Foundation Young Investi-gator Fellowship in 2005. During my time with Brian, I learned about the many advantages of an EHA Fellowship, both the fi-nancial support, as well as the opportunity to become part of the European hematology community.

My EHA José Carreras Foundation Young Investigator Fellow-ship will be used to study the role of the homeobox transcrip-tion factor CDX2 in the pathogenesis of acute myeloid leukemia (AML). In a collaborative project between my home institution and the Gilliland Laboratory at Harvard University, it was previ-ously discovered that the CDX2 gene was expressed in the leu-kemic cells from the majority of adult patients with AML, whereas CDX2 expression was undetectable in the normal adult hematopoietic compartment. Furthermore, we and oth-ers have demonstrated the functional relevance of aberrant CDX2 expression in a series of in vitro and in vivo experiments. For instance, CDX2 enhanced the capacity of myeloid progeni-tor cells to self-renew, an important functional attribute of most, if not all, AML subtypes, suggesting that CDX2 may be a common downstream effector of different leukemogenic path-ways. Expression of CDX2 led to dysregulation of Hox genes, known transcriptional targets of CDX family members during development, supporting a potential role of CDX2 in the devel-opment of human AML with aberrant HOX gene expression. Since the consequences of aberrant CDX2 expression have not been studied using unbiased approaches that require no prior

knowledge about the normal functions of CDX2, other gene products that mediate the leukemogenic effects of CDX2, in-cluding potentially therapeutic mole-cules, are not known.

A particularly enticing aspect of these observations is that aberrant expression of CDX2 appears to affect the majority of AML patients. Thus, understanding mechanisms of transformation mediated by CDX2 are likely to be of value for the

broad spectrum of AML, and not solely for selected genetic or morphologic subtypes. Furthermore, although it is challenging to target transcription factors therapeutically, evolving tech-nologies may enable novel approaches for treatment. For ex-ample, large-scale RNA interference (RNAi) screens for syn-thetic lethal interactions, and unbiased small-molecule screens have potential to identify compounds or pathways that will effectively target CDX2 overexpression in AML.

The goals of my project are to characterize the transcriptional changes induced by ectopic expression of CDX2 in hematopoi-etic stem and progenitor cells in vitro. Another goal is to deter-mine the gene-expression profiles of murine leukemias in-duced by ectopic expression of CDX2 in hematopoietic stem and progenitor cells in vivo. Furthermore to determine the transcriptional changes associated with genetic inhibition of CDX2 in human AML cell lines and to identify candidate down-stream effectors of aberrant CDX2 expression in myeloid leu-kemogenesis through bioinformatic analyses, cross-species comparisons, and integration of the results from experimental models of hematopoietic transformation with gene-expression profiles and clinical data from patients with AML. Lastly we want to experimentally validate candidate downstream effec-tors of aberrant CDX2 expression in myeloid leukemogenesis. Longer-term ambitions include a genome-wide RNAi-based functional genetic strategy to identify genes that are essential for the viability and proliferation of leukemic cells specifically in the context of aberrant CDX2 expression.

The generous funding provided by the EHA José Carreras Foundation Young Investigator Fellowship is of critical impor-tance for the realization of these goals. More broadly, I believe that initiatives like the EHA Fellowship Program will encourage young investigators, especially those who are trained as physi-cians, to commit themselves to a career in hematologic re-search.

Stefan FröhlingWinner of the EHA José Carreras Foundation Young Investigator Fellowship 2008University Hospital of Ulm, Germany

W Fibbe presents Stefan Fröhling with the award


> The wine industry extols the merits of drinking wine, and we all marvel at the proposed health benefits. We mentioned the possible benefits of resveretrol in previous newsletters but decided that the amount of wine required daily to pro-vide a protective effect would probably induce severe liver damage, thereby ne-gating any putative benefit. However things might be getting better! In a study, published by Richard Weindruch and col-leagues, from the University of Wiscon-sin-Madison, (PloS ONE 2008:3: e2264) they claimed that mice given low dose resveretrol were protected from heart disease. They report that low dose resv-eretrol inhibits gene expression profiles associated with cardiac and skeletal muscle aging, and prevents age-related cardiac dysfunction. Dietary resveretrol also mimics the effects of calorie restric-tion in insulin mediated glucose uptake in muscle. Gene expression profiling suggests that resveretrol may retard some aspects of aging through altera-tions in chromatin structure and tran-scription. Resveretrol, at doses that can be readily achieved in humans (three to

Wine and health: End of Road for French Paradox?Giovanni Morelli, EHA's resident wine authority, updates us on the resveretrol

heart health story, and delivers a mixed bag of news for wine lovers. A

decline in wine consumption in France and craving for fast food is being

balanced by EU initiatives to expand production of quality wine.

four glasses of red wine daily), fulfills the definition of a dietary compound that mimics some aspects of calorie restric-tion. Some may feel three to four glasses of wine daily to be excessive and that perhaps one or two glasses of wine sup-plemented with oral resveretrol would do the trick.A lot of this type of research is based on the so-called 'French paradox'. However the bad news is that the French are re-ducing their intake of red wine and tak-ing to fast-food. Yes, less than 50 percent of young people in France are drinking wine and only 10 percent consume it regularly! In 1980 the average consump-tion of wine in France was 120 liters per year and this has fallen by 50 percent. Paradoxically wine drinking in America in the 21 – 29 year age group is the most rapidly growing segment of the world market. What is more worrying is the loss of eat-ing habits and the craving for fast foods. The number of family meals and busi-ness lunches has decreased by 50 per-cent in the last 10 years in France and obesity is on the increase. Diana Macle writing in the Wine Spectator quotes Professor Francois d’Hauteville as say-ing: ‘The young people I interviewed rec-ognized that wine was part of French culture and identity but they know very little about it, and many didn’t even like the taste!' Perhaps the French Paradox will become a thing of the past.Another interesting use of resveretrol is in the treatment of MELAS. This syn-drome, characterized by mitochondrial myopathy, encephalopathy, lactic acido-sis and stroke-like episodes, is caused by mitochondrial dysfunction and is cur-rently undergoing a randomized trial us-ing resveretrol (STR501) as a mitochon-drial stimulant!As physicians we all have become aware of a number of drug scandals recently,

Wine tasting can be fun unless taken too seriously!

but the wine business is not immune from controversy. In Montalcino, that most beautiful of hill towns in Tuscany, their high priced Brunellos have come under scrutiny. The public prosecutor in Siena, Nino Calabrese, is investigating famous names including Frescobaldi and Banfi for possibly using grapes other than Sangiovese or importing grapes from other areas. In the US billionaire wine collector, William Koch - no rela-tion as far as I am aware to Robert Koch who in 1890 established the etiology of Anthrax and Tuberculosis - found that wines that he had bought were not in fact part of Thomas Jefferson’s collection as he had been led to believe! He paid a large amount of money for his mistake!

There is a huge surplus of wine (mostly poor quality) in Europe today, illustrated by the fact that in 2006 the EU spent € 2 billion distilling surplus wine into indus-trial alcohol! Marianne Fischer Boel, EU agriculture commissioner, is trying to help by convincing small growers to re-tire and pull out 400,000 acres of vines and subsequently to phase out distilla-tion subsidies. Michael Mann, spokes-man for the EU agriculture and rural de-velopment department, is quoted as saying: ‘In the short term production will decrease but when planting restrictions go, there is no reason why production of quality wine should not expand’. For both our heart health and drinking pleasure, let us hope that both Weindruch and Mann prove correct.

Giovanni Morelli

Giovanni Morelli is a hematologist who divides his time between Dublin and TuscanyAll grapes are green in the beginning


> SPC member by appointmentFirst some background information. The SPC consists of 10 full members who are appointed by the EHA-Board. The Congress President serves as the 11th member of the SPC for one year. All other SPC members serve for two years, except for the SPC chair, who serves for three years. The chair of the SPC is ap-pointed by the Executive Board as chair of both the SPC and the SPC Advisory Board (SPC-AB). The SPC is responsible for the important task of putting together the scientific and educa-tion program for the entire EHA Congress.

Every year one former chair and 3-4 full members rotate off the SPC and are replaced by the EHA-Board. The 10 full mem-bers of the SPC should cover the entire field of hematology. A minimum of two full members of the SPC should also be mem-bers of the EHA Board and at least one full member of the SPC is also member of the EHA Education Committee to ensure co-ordination between the activities of the two committees. The EHA Education Committee is primarily involved in the develop-

The Scientific Program Committee (SPC) and SPC Advisory Board (SPC AB):how does it work?Preparations for the 14th EHA congress, to be held in Berlin, Germany (June 4-7, 2009) are now full steam ahead. For

every congress, the EHA Board appoints a Scientific Program Committee (SPC), whose role is to compose a program for

the annual congress that meets the highest scientific and educational standards. The SPC is supported by members of

the EHA Executive Office under the lead of Rik Craenmehr, who serves as the Congress Assistant, with the remit of

assuring an efficient and reliable organization.

ment of educational activities outside the annual congress. Fi-nally, one member of the SPC is responsible for maintaining the database of abstract reviewers. This database is checked annually for accuracy, areas of expertise and balance with re-spect to gender and nationality of reviewers.

How do SPC and SPC AB work?The SPC will receive support from the SPC-AB, which submits suggestions for the invited speakers program and contributes to selecting the abstracts for presentation at the congress. The SPC-AB consists of 20-25 members, who serve for 1-2 years and are eligible to serve on the SPC.Every year, about 12 members rotate off the SPC-AB and 12 new members are appointed. The SPC-AB should be balanced for the different areas of expertise, stages of career, gender, and nationality. The EHA Board approves and appoints the SPC-AB, after receiving suggestions by the SPC chair.

The Scientific Program Committee and the Advisory Board have two principal tasks. One is to choose the invited speakers and their topics.Both members of SPC and SPC AB are expected to submit pro-posals. The proposals are collected in August and discussed during the meeting of the SPC in September. A selection of top-ics and speakers is made during this meeting and the program is prepared and finalized during the last months of the year.

The second task of the SPC and SPC-AB members is to review submitted abstracts and to select abstracts for poster or oral presentation. This takes place during a meeting in the first week of April 2009. I would like to encourage you and your col-leagues to submit abstracts for EHA-14. Please remember that there are up to 80 travel grants that are assigned in the order of the ranking that an abstract receives. In previous years all abstracts selected for oral presentation and a substantial num-ber of posters received a travel grant. The deadline for abstract submission is March 1, 2009.

I look forward to seeing you in Berlin!

Radek Skoda, SPC Chair for EHA-14University Hospital Basel, Switzerland

Radek Skoda


WWW.EHAWEB.ORG

0

1000

2000

3000

4000

5000

6000

7000

1s t 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th

0

1000

2000

3000

4000

5000

6000

7000

1s t 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th

6672

WWW.EHAWEB.ORG

Top 10 countries: registrations2008: 2007:

• Italy 680 474• United Kingdom 453 349• France 455 390• Greece 383 317• Spain 364 300• United States of America 337 214• Germany 329 277• Switzerland 216 214• The Netherlands 213 180• Denmark 181 88

WWW.EHAWEB.ORG

Registrations per continent

81%

7%5%3%1%3%

EuropeAsiaNorth AmericaSouth AmericaAustraliaAfrica

> Altogether nearly 1800 abstracts were submitted. During the Presidential Symposium the five best abstracts were pre-sented and 80 oral presenters were awarded with travel grants of € 500 and free congress registration. Once again, the red-capped EHA ‘poster walkers’ proved a popular draw, encour-aging lively discussions among interested delegates.

Two outstanding hematologists were honored in Copenhagen. The EHA José Carreras Award was made to Professor John Goldman (Imperial College London, United Kingdom), while Professor Dieter Hoelzer (University Frankfurt, Germany) re-ceived the EHA Jean Bernard Lifetime Achievement Award.

Copenhagen hosts 13th EHA Congress The 13th Congress of the European Hematology

Association (EHA) in Copenhagen (June 12-15, 2008)

will be remembered as yet another successful event in

the annals of EHA congress.

The meeting attracted over 6600 delegates from 103

countries, who enjoyed a wide ranging scientific

program of the highest quality.

Professor Goldman has played an important role in one of the major success stories of leukemia therapy, with his work con-tributing to the fact that chronic myeloid leukemia (CML) pa-tients can now hope to live normal life spans.Professor Goldman was a pioneer in the use of bone marrow transplants in CML, a therapy that became the standard of care for two decades. In the late 1990s, when new drugs were de-veloped to block the effects of the genetic changes causing CML, Professor Goldman led the efforts to develop new tech-nologies to detect residual levels of CML.

Professor Hoelzer, head of the Institute for Hematology at the University of Frankfurt am Main, has contributed to many of the recent advances in treatment of adult acute lymphoblastic leukemia (ALL).

He set up a cross-German study group involving more than 100 hospitals to examine therapies and their effectiveness in treat-ment of ALL, at a time when the disease had a cure rate of less than 10 percent. The study group contributed to substantial

Registrations 1994-2008

Registrations per continent

Top 10 countries: registrations

Bella Center in Copenhagen, Denmark

EHA-CME desks


WWW.EHAWEB.ORG0

200

400

600

800

1000

1200

1400

1600

1800

2000

2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th

1892

improvements in the diagnosis of ALL and the development of targeted, therapies. Tailored therapy for ALL is very important as 95 percent of people with the disease show individual pat-terns in their leukemic cells. This individualized approach, which Professor Hoelzer championed, has resulted in cure rates for ALL of 50 percent .

The EHA-ASH policy forum in Copenhagen titled ‘Relation be-tween academia and pharma: public trust at stake?’ focused on good governance. Both EHA and American Society of Hema-tology (ASH) have long standing, good relations with the phar-maceutical industry, which remains crucial for the core activi-ties of both associations.

The Molecular Hematopoiesis Workshop was organized for the second year running. Following last year’s success a big-ger room was allocated and again the room was filled to ca-pacity with enthusiastic delegates. The aim of this workshop is to present cutting edge hematological science in a new and dynamic way. Thanks to the efforts of both speakers and or-

Abstracts 1996-2008

ganizers (Tariq Enver, Tony Green, Dan Tenen and Ivo Touw) an exciting addition has been made to regular congress edu-cational sessions. The meet-the expert sessions were suc-cessfully moved to lunch hours, with participants appreciat-ing the interactive opportunities they provided.

The poster area attracted many visitors

Exhibition area

N Borregaard, Congress President

M Greaves at the EHA-ASH policy forum

The EHA booth in the Center Hall


WWW.EHAWEB.ORG

Top 10 countries: abstracts2008: 2007:

• Italy 369 299• Spain 131 146 • Greece 102 115• United Kingdom 101 114 • Germany 99 134• France 76 103• United States of America 84 62• Czech Republic 74 74• Romania 60 39• The Netherlands 58 24

WWW.EHAWEB.ORG

145

884488

274 Oral

Poster

Publication Only

Rejected

Abstract selection

13th Congress in Copenhagen

WWW.EHAWEB.ORG

145

884488

274 Oral

Poster

Publication Only

Rejected

Abstract selection

13th Congress in Copenhagen

WWW.EHAWEB.ORG

Participation devided by age

1931-19401% 1920-1930

1%

1981-XXXX1%

1951-196034%

1941-195011%

1961-197033%

1971-198019%

1920-1930

1931-1940

1941-1950

1951-1960

1961-1970

1971-1980

1981-XXXX

Top 10 countries: abstracts Abstracts selection 13th Congress in Copenhagen

Participation divided by age

The 13th Congress also provided a platform for European working groups and network meetings. Besides scientific sessions there were also many other possibilities to meet, including the social evening, the Farewell Lunch, the exhibition and poster sessions.

It is our privilege to express our gratitude to the sponsors of the meeting, the Scientific Program Committee, the Advisory Board, the Local Organizing Committee, EHA Board and Exec-utive Office and all the individuals who worked so hard to make the 13th Congress of EHA a resounding success.

Niels Borregaard Gilles SallesCongress President Chair Scientific Program Committee13th Congress 13th Congress

D Hoelzer receives the Jean Bernard Lifetime Achievement Award

Nearly all the sessions were webcasted


Collaboration between EHA and the European School of Haematology (ESH)

> Scientific workshops are smaller scale meetings on dedi-cated topics of relevance for hematology. They are intended to promote informal interaction and discussion between scien-tists and clinicians working in the field. Another part of joint projects are the interactive hematology tutorials. Hematology tutorials are annual courses aiming to provide laboratory and clinical hematologists with an integrated diagnostic and clini-cal work-up of hematological disorders.

A new logo was designed to give ‘face’ to the new style collabo-ration.

European Sc

hool

of H

aem

atol

ogy

Europ

ean Hematology Association

EHA and the European School of Haematology (ESH) have collaborated on several projects in the past. In February 2008

the Joint Executive Committee was established to formalize the collaboration for future events and new projects. The

committee representing both organizations includes W Fibbe, R Foà, E Gluckman and B Löwenberg. Selection of topics

for workshops and development of new initiatives are amongst the most important tasks of this committee.

ESH-EHA Joint Activities in 2009ESH-EHA Scientific Workshop: Leukemic and Cancer Stem CellsApril 3-5, 2009, Mandelieu, FranceChairs: C Chomienne, D Bonnet, P Valent and D LouvardESH-EHA Hematology Tutorial: Hematology Tutorial on Lymphoid Malignancies May 15 - 17, 2009, Tallinn, EstoniaChairs: R Foà, E Kimby and G ZiniESH-EHA Scientific Workshop: Innovative Therapies for Red Cell and Iron Related DisordersNovember 6 – 8, 2009Coordinators: Y Beuzard and C CamaschellaESH-EHA Annual Diagnostic Workup of Hematological Malignancies: Focus on Chronic DiseasesAutumn 2009Chairs: B Bain, R Foà, G Zini

For information on the tutorials or workshops please visit: www.esh.org or www.ehaweb.org

Tutorials are part of the joint activities by EHA and ESH.


Please be encouraged to send in your scenic photographs for future newsletter covers (size: standing).The EHA offers € 100 for the photograph chosen as cover photo, starting next issue.

November 2008 May 2008 November 2007 May 2007

Cover photographs

Croatia United States Denmark SwitzerlandAdriana Neghina (RO) Marc Rudoltz (USA) Martin Lorenzen (DK) Karin Amrein (CH)

EHA Members 3,000

Benefits of EHA Membership

- Subscription to Haematologica/ The Hematology Journal (impact factor 5.516) - Reduction of € 180 on the individual registration fee for the EHA Annual Congress (junior members receive a reduction of € 105).

- Eligible to apply for EHA Research Fellowships & Grants - Entitled to apply for a scholarship to attend ESH-EHA Scientific Workshops - EHA Newsletter - Access to the webcast of the EHA annual congress - Access to the EHA membership database

> The EHA Newsletter encourages its readers to share their opinions through letters to the editor.We would like to hear your ideas on any topic in hematology. We would also appreciate your views on the Newsletter, favor-able or not!Letters must be short (maximum of 300 words) and may be edited.

If you are interested in having your Letter to the Editor pub-

‘Letter to the Editor’lished, please be sure to include your full name and accurate contact information. Anonymous letters to the editor cannot be published.E-mail us at [email protected]

The EHA Newsletter EditorsShaun McCannCatherine Lacombe


EHA CME UnitF Lo Coco, Italy (Chair)D Loukopoulos, Greece J Musial, Poland A Prentice, United Kingdom

EHA Corporate Sponsor CommitteeU Jäger, Austria (Chair)E Berntorp, SwedenH Döhner, GermanyI Touw, The Netherlands

EHA Curriculum CommitteeE Hellström-Lindberg, Sweden (Chair)L Degos, France C Hok Toh, United KingdomW Ludwig, Germany P Rebulla, ItalyA Urbano Ispizua, Spain

EHA Education CommitteeA Green, United Kingdom (Chair)M Arat, TurkeyE Berntorp, SwedenC Chomienne, FranceC Craddock, United KingdomL Degos, FranceW Fibbe, NetherlandsE Hellström-Lindberg, SwedenD Jasmin, FranceF Lo Coco, ItalyH Serve, Germany

EHA Fellowships and Grants CommitteeC Lacombe, France (Chair)C Camaschella, Italy I Touw, The Netherlands

EHA Governance CommitteeE Berntorp, Sweden (Chair)C Camaschella, ItalyJ Goldman, United Kingdom U Jäger, AustriaE Montserrat, Spain

EHA Local Organizing Committee 14th CongressR Hehlmann, Germany (Congress President)B Dörken, GermanyD Niederwieser, GermanyE Thiel, Germany

EHA Membership CommitteeI Touw, The Netherlands (Chair)M Guenova, BulgariaB Huntly, United KingdomI Roberts, United Kingdom

EHA Nomination CommitteeI Pabinger, Austria (Chair)A Biondi, ItalyM Björkholm, SwedenB Löwenberg, The NetherlandsA Urbano Ispizua, Spain

EHA Press Committee 2009A Hagenbeek, The Netherlands (Chair)R. Hehlman, GermanyW Fibbe, The NetherlandsI Roberts, United KingdomR Skoda, Switzerland

EHA Publication CommitteeW Fibbe, The Netherlands (Chair)M Cazzola, Italy R Foà, Italy C Lacombe, France S McCann, Ireland

EHA Scientific Program Committee 14th Congress (SPC)R Skoda, Switzerland (Chair)H Büller, The NetherlandsC Chomienne, FranceJ Cools, BelgiumR Hehlmann, Germany (Congress President)F Lo Coco, ItalyC Niemeyer, GermanyI Peake, United KingdomG Salles, FranceS Thein, United KingdomM Theobald, The Netherlands

EHA Scientific Program Committee Advisory Board 14th CongressN Avent, United KingdomM Baccarini, ItalyC Beamont, FranceE Berntorp, SwedenJ Cornelissen, The NetherlandsC Craddock, United KingdomN Cross, United KingdomT Enver, United KingdomC Gachet, ItalyG Gaidano, ItalyP Ghia, ItalyW Hofmann, GermanyB Huntly, United KingdomJ Ingerslev, DenmarkS Izraeli, IsraelB Lämmle, SwitzerlandL Malcovati, ItalyM Manz, SwitzerlandR Pieters, The NetherlandsM Piris, SpainJ San Miguel, Spain

Overview EHA Committees and Units

B Schlegelberger, GermanyR Schlenk, GermanyM Trneny, Czech RepublicA Urbano Ispizua, SpainA Waage, Norway

EHATol UnitG Zini, Italy (Editor)B Bain, United KingdomW Erber, United KingdomR Foà, ItalyM Rozman, Spain M van ‘t Veer, The Netherlands


ColophonThe EHA Newsletter is published by the European Hematology Association twice a year. Membership of the European Hematology Association includes subscription to the EHA Newsletter.

EditorsEditor-in-Chief Shaun McCannEditor Catherine LacombeSub-editor Janet FrickerEditorial Coordination Ineke van der Beek

Photography & IllustrationsCover Adriana Neghina MD, Romania (Plitvice National Park – Croatia)Congress photographs Moritz WustingerCartoon Jim CoganPicture of tutorial Angela de Vlaming

PrintingDrukkerij BibloVanGerwen, ’s-Hertogenbosch

Contact editorsFor general remarks, questions and suggestions e-mail [email protected]

Current members of the EHA BoardWillem Fibbe – President 2007 – 2009 – The Netherlands

Robin Foà – President Elect 2007-2009 – Italy

Eva Hellstrom-Lindberg – Past President 2007-2009 – Sweden

Hartmut Döhner – Treasurer 2009-2010 – Germany

Irene Roberts – Secretary 2006-2009 – United Kingdom

Erik Berntorp – 2005-2009 – Sweden

Clara Camaschella – 2007-2011 – Italy

Christine Chomienne – 2007-2011 – France

Ulrich Jäger – 2006-2010 – Austria

Catherine Lacombe – 2005-2009 – France

Jorge Sierra – 2008-2012 – Spain

Radek Skoda – 2006-2010 – Switzerland

Ivo Touw – 2006-2010 – The Netherlands

Upcoming Congresses

> 14th Congress of the EHA Date: June 4-7, 2009 Place: Berlin, Germany Congress President: Prof R Hehlmann

> 15th Congress of the EHA Date: June 10 – 13, 2010Place: Barcelona, SpainCongress President: Prof J San Miguel

> 16th Congress of EHA Date: June 9-12, 2011 Place: London, United Kingdom Congress President: Prof I Roberts

Barcelona

London

Berlin


EHA Executive Office

Victoria ZhuravlevaEducation

Contact Information

EHA Executive OfficeWestblaak 713012 KE RotterdamThe Netherlands

Phone +31 (0)10 4361 760Fax: +31(0)10 4361 817E-mail: [email protected]: www.ehaweb.org

Carin SmandManaging Director

Ans SteutenExecutive

ManagementFellowships &

Grants

Petra StorkPublication &

Communication

Ineke van der BeekExternal Affairs

National Societies

Thom Duyvené de Wit

CME

Djowrain BouterseOffice Manager

Rik CraenmehrCongress Assistant

Annemiek KuijstenAnnual Congress

Sponsor Program

Liz StokesAssistant to

Managing Director

Angela de VlamingMembership


the offi cial newsletter for members of the EHA

EHA Executive Offi ce

Westblaak 713012 KE ROTTERDAMThe NetherlandsT. +31 (0)10 436 17 60F. +31 (0)10 436 18 17E. [email protected]. www.ehaweb.org

Contributors

Bronze Sponsor

Gold Sponsors

Corporate Sponsors 2008

Newsletter November 2008

Documents

Transcript of Newsletter November 2008